Cardioprotective growth factors

Cardiovascular Research

Volumn 83, Issue 2, 2009, Pages 179-194

  Hausenloy, Derek J ^a   Yellon, Derek M ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Cardioprotection; Growth factors; Ischaemia; Reperfusion

Indexed keywords

ADENOVIRUS VECTOR; CARDIOTROPHIN 1; FIBROBLAST GROWTH FACTOR 1; FIBROBLAST GROWTH FACTOR 2; FIBROBLAST GROWTH FACTOR 4; GROWTH FACTOR; INSULIN; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE KINASE 2; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; RECOMBINANT VASCULOTROPIN; SOMATOMEDIN B; SOMATOMEDIN C; TRANSFORMING GROWTH FACTOR BETA; TYROSINE KINASE RECEPTOR; UROCORTIN; VASCULOTROPIN;

ACUTE HEART INFARCTION; ANGIOGENESIS; CONTINUOUS INFUSION; DRUG EFFICACY; DRUG SAFETY; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HEART MUSCLE REVASCULARIZATION; HEART PROTECTION; HUMAN; INOTROPISM; MONOTHERAPY; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN FUNCTION; REPERFUSION INJURY; REVIEW; SIGNAL TRANSDUCTION; STEM CELL TRANSPLANTATION;

ANIMALS; CYTOKINES; GENE THERAPY; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MYOCARDIAL REPERFUSION INJURY; MYOCARDIUM; PROTEIN KINASES; RECEPTOR PROTEIN-TYROSINE KINASES; SIGNAL TRANSDUCTION; STEM CELL TRANSPLANTATION; STEM CELLS; TRANSFORMING GROWTH FACTOR BETA; UROCORTINS;

EID: 67650263713     PISSN: 00086363     EISSN: 17553245     Source Type: Journal    
DOI: 10.1093/cvr/cvp062     Document Type: Review

References (178)

1. Hausenloy DJ, Yellon DM. New directions for protecting the heart against ischaemia-reperfusion injury: targeting the Reperfusion Injury Salvage Kinase (RISK)-pathway. Cardiovasc Res 2004;61:448-460.
2. Hausenloy DJ, Yellon DM. Survival kinases in ischemic preconditioning and postconditioning. Cardiovasc Res 2006;70:240-253.
3. Hausenloy DJ, Yellon DM. Reperfusion injury salvage kinase signalling: taking a RISK for cardioprotection. Heart Fail Rev 2007;12:217-234.
4. Burley DS, Hamid SA, Baxter GF. Cardioprotective actions of peptide hormones in myocardial ischemia. Heart Fail Rev 2007;12:279-291.
5. Riksen NP, Hausenloy DJ, Yellon DM. Erythropoietin: ready for prime- time cardioprotection. Trends Pharmacol Sci 2008;29:258-267.
6. Karmazyn M, Purdham DM, Rajapurohitam V, Zeidan A. Signalling mechanisms underlying the metabolic and other effects of adipokines on the heart. Cardiovasc Res 2008;79:279-286.
7. Yellon DM, Baxter GF. Reperfusion injury revisited: is there a role for growth factor signaling in limiting lethal reperfusion injury? Trends Cardiovasc Med 1999;9:245-249.
8. Murry CE, Jennings RB, Reimer KA. Preconditioning with ischemia: a delay of lethal cell injury in ischemic myocardium. Circulation 1986; 74:1124-1136.
9. Zhao ZQ, Corvera JS, Halkos ME, Kerendi F, Wang NP, Guyton RA et al. Inhibition of myocardial injury by ischemic postconditioning during reperfusion: comparison with ischemic preconditioning. Am J Physiol Heart Circ Physiol 2003;285:H579-H588.
10. Hausenloy DJ, Yellon DM. Preconditioning and postconditioning: united at reperfusion. Pharmacol Ther 2007;116:173-191.
11. Hausenloy DJ, Wynne AM, Yellon DM. Ischemic preconditioning targets the reperfusion phase. Basic Res Cardiol 2007;102:445-452.
12. Juhaszova M, Zorov DB, Kim SH, Pepe S, Fu Q, Fishbein KWet al. Glyco- gen synthase kinase-3beta mediates convergence of protection signaling to inhibit the mitochondrial permeability transition pore. J Clin Invest 2004;113:1535-1549.
13. Davidson SM, Hausenloy D, Duchen MR, Yellon DM. Signalling via the reperfusion injury signalling kinase (RISK) pathway links closure of the mitochondrial permeability transition pore to cardioprotection. Int J Biochem Cell Biol 2006;38:414-419.
14. Hausenloy DJ, Yellon DM. The mitochondrial permeability transition pore: its fundamental role in mediating cell death during ischaemia and reperfusion. J Mol Cell Cardiol 2003;35:339-341.
15. Costa AD, Jakob R, Costa CL, Andrukhiv K, West IC, Garlid KD. The mechanism by which the mitochondrial ATP-sensitive K+ channel opening and H2O2 inhibit the mitochondrial permeability transition. J Biol Chem 2006;281:20801-20808.
16. Abdallah Y, Gkatzoflia A, Gligorievski D, Kasseckert S, Euler G, Schluter KD et al. Insulin protects cardiomyocytes against reoxygenation-induced hypercontracture by a survival pathway targeting SR Ca2+ storage. Cardiovasc Res 2006;70:346-353.
17. Mensah K, Mocanu MM, Yellon DM. Failure to protect the myocardium against ischemia/reperfusion injury after chronic atorvastatin treatment is recaptured by acute atorvastatin treatment: a potential role for phosphatase and tensin homolog deleted on chromosome ten?J Am Coll Cardiol 2005;45:1287-1291.
18. Lecour S, Suleman N, Deuchar GA, Somers S, Lacerda L, Huisamen B et al. Pharmacological preconditioning with tumor necrosis factor-alpha activates signal transducer and activator of transcription-3 at reperfusion without involving classic prosurvival kinases (Akt and extracellular signal-regulated kinase). Circulation 2005;112:3911-3918.
19. Boengler K, Buechert A, Heinen Y, Roeskes C, Hilfiker-Kleiner D, Heusch G et al. Cardioprotection by ischemic postconditioning is lost in aged and STAT3-deficient mice. Circ Res 2008;102:131-135.
20. Garlid KD, Costa AD, Cohen MV, Downey JM, Critz SD. Cyclic GMP and PKG activate mito K(ATP) channels in isolated mitochondria. Cardiovasc J S Afr 2004;15:S5.
21. Zatta AJ, Kin H, Lee G, Wang N, Jiang R, Lust R et al. Infarct-sparing effect of myocardial postconditioning is dependent on protein kinase C signalling. Cardiovasc Res 2006;70:315-324.
22. Jin ZQ, Karliner JS, Vessey DA. Ischaemic postconditioning protects isolated mouse hearts against ischaemia/reperfusion injury via sphingosine kinase isoform-1 activation. Cardiovasc Res 2008;79:134-140.
23. Cantley LC. The phosphoinositide 3-kinase pathway. Science 2002;296: 1655-1657.
24. Oudit GY, Sun H, Kerfant BG, Crackower MA, Penninger JM, Backx PH. The role of phosphoinositide-3 kinase and PTEN in cardiovascular physiology and disease. JMol Cell Cardiol 2004;37:449-471.
25. Murphy LO, Blenis J. MAPK signal specificity: the right place at the right time. 7rends Biochem Sci 2006;31:268-275.
26. Gospodarowicz D. Localisation of a fibroblast growth factor and its effect alone and with hydrocortisone on 3T3 cell growth. Nature 1974;249:123-127.
27. Detillieux KA, Sheikh F, Kardami E, Cattini PA. Biological activities of fibroblast growth factor-2 in the adult myocardium. Cardiovasc Res 2003;57:8-19.
28. Kardami E, Detillieux K, Ma X, Jiang Z, Santiago JJ, Jimenez SK et al. Fibroblast growth factor-2 and cardioprotection. Heart Fail Rev 2007; 12:267-277.
29. Kapur NK, Rade JJ. Fibroblast growth factor 4 gene therapy for chronic ischemic heart disease. Trends Cardiovasc Med 2008;18:133-141.
30. Yanagisawa-Miwa A, Uchida Y, Nakamura F, Tomaru T, Kido H, Kamijo T et al. Salvage of infarcted myocardium by angiogenic action of basic fibroblast growth factor. Science 1992;257:1401-1403.
31. Padua RR, Sethi R, Dhalla NS, Kardami E. Basic fibroblast growth factor is cardioprotective in ischemia-reperfusion injury. Mol Cell Biochem 1995;143:129-135.
32. Horrigan MC, MacIsaac AI, Nicolini FA, Vince DG, Lee P, Ellis SG et al. Reduction in myocardial infarct size by basic fibroblast growth factor after temporary coronary occlusion in a canine model. Circulation 1996;94:1927- 1933.
33. Htun P, Ito WD, Hoefer IE, Schaper J, Schaper W. Intramyocardial infusion of FGF-1 mimics ischemic preconditioning in pig myocardium. JMol Cell Cardiol 1998;30:867-877.
34. Jiang ZS, Padua RR, Ju H, Doble BW, Jin Y, Hao J et al. Acute protection of ischemic heart by FGF-2: involvement of FGF-2 receptors and protein kinase C. Am J Physiol Heart Circ Physiol 2002;282:H1071-H1080.
35. Cuevas P, Carceller F, Martinez-Coso V, Cuevas B, Fernandez-Ayerdi A, Reimers D et al. Cardioprotection from ischemia by fibroblast growth factor: role of inducible nitric oxide synthase. Eur J Med Res 1999;4:517-524.
36. Padua RR, Merle PL, Doble BW, Yu CH, Zahradka P, Pierce GN et al.FGF-2-induced negative inotropism and cardioprotection are inhibited by chelerythrine: involvement of sarcolemmal calcium-independent protein kinase C. J Mol Cell Cardiol 1998;30:2695-2709.
37. Doble BW, Chen Y, Bosc DG, Litchfield DW, Kardami E. Fibroblast growth factor-2 decreases metabolic coupling and stimulates phosphorylation as well as masking of connexin43 epitopes in cardiac myocytes. Circ Res 1996;79:647-658.
38. Jiang ZS, Srisakuldee W, Soulet F, Bouche G, Kardami E. Non-angiogenic FGF-2 protects the ischemic heart from injury, in the presence or absence of reperfusion. Cardiovasc Res 2004;62:154-166.
39. Sheikh F, Sontag DP, Fandrich RR, Kardami E, Cattini PA. Overexpression of FGF-2 increases cardiac myocyte viability after injury in isolated mouse hearts. Am J Physiol Heart Circ Physiol 2001;280:H1039-H1050.
40. Meij JT, Sheikh F, Jimenez SK, Nickerson PW, Kardami E, Cattini PA. Exacerbation of myocardial injury in transgenic mice overexpressing FGF-2 is T cell dependent. Am J Physiol Heart Circ Physiol 2002;282: H547-H555.
41. House SL, Bolte C, Zhou M, Doetschman T, Klevitsky R, Newman G et al. Cardiac-specific overexpression of fibroblast growth factor-2 protects against myocardial dysfunction and infarction in a murine model of low-flow ischemia. Circulation 2003;108:3140-3148.
42. Virag JA, Rolle ML, Reece J, Hardouin S, Feigl EO, Murry CE. Fibroblast growth factor-2 regulates myocardial infarct repair: effects on cell proliferation, scar contraction, and ventricular function. Am J Pathol 2007; 171:1431-1440.
43. Simons M, Annex BH, Laham RJ, Kleiman N, Henry T, Dauerman H et al. Pharmacological treatment of coronary artery disease with recombinant fibroblast growth factor-2: double-blind, randomized, controlled clinical trial. Circulation 2002;105:788-793.
44. Ahn A, Frishman WH, Gutwein A, Passeri J, Nelson M. Therapeutic angio- genesis: a new treatment approach for ischemic heart disease-part I. Cardiol Rev 2008;16:163-171.
45. Takahashi N, Seko Y, Noiri E, Tobe K, Kadowaki T, Sabe H et al. Vascular endothelial growth factor induces activation and subcellular translocation of focal adhesion kinase (p125FAK) in cultured rat cardiac myo- cytes. Circ Res 1999;84:1194-1202.
46. Ladoux A, Frelin C. Hypoxia is a strong inducer of vascular endothelial growth factor mRNA expression in the heart. Biochem Biophys Res Commun 1993;195:1005-1010.
47. Levy AP, Levy NS, Loscalzo J, Calderone A, Takahashi N, Yeo KT et al. Regulation of vascular endothelial growth factor in cardiac myocytes.Circ Res 1995;76:758-766.
48. Lee SH, Wolf PL, Escudero R, Deutsch R, Jamieson SW, Thistlethwaite PA. Early expression of angiogenesis factors in acute myocardial ischemia and infarction. N Engl J Med 2000;342:626-633.
49. Luo Z, Diaco M, Murohara T, Ferrara N, Isner JM, Symes JF. Vascular endothelial growth factor attenuates myocardial ischemia-reperfusion injury. Ann 7horac Surg 1997;64:993-998.
50. Seko Y, Takahashi N, Tobe K, Ueki K, Kadowaki T, Yazaki Y. Vascular endo- thelial growth factor (VEGF) activates Raf-1, mitogen-activated protein (MAP) kinases, and S6 kinase (p90rsk) in cultured rat cardiac myocytes. J Cell Physiol 1998;175:239-246.
51. Gerber HP, McMurtrey A, Kowalski J, Yan M, Keyt BA, Dixit V et al. Vascular endothelial growth factor regulates endothelial cell survival through the phosphatidylinositol 3'-kinase/Akt signal transduction pathway. Requirement for Flk-1/KDR activation. J Biol Chem 1998;273:30336-30343.
52. Kawata H, Yoshida K, Kawamoto A, Kurioka H, Takase E, Sasaki Yet al. Ischemic preconditioning upregulates vascular endothelial growth factor mRNA expression and neovascularization via nuclear translocation of protein kinase C epsilon in the rat ischemic myocardium. Circ Res 2001;88:696-704.
53. Thirunavukkarasu M, Addya S, Juhasz B, Pant R, Zhan L, Surrey S et al. Heterozygous disruption of Flk-1 receptor leads to myocardial ischaemia reperfusion injury in mice: application of affymetrix gene chip analysis. J Cell Mol Med 2008; 12:1284-1302.
54. Addya S, Shiroto K, Turoczi T, Zhan L, Kaga S, Fukuda S et al. Ischemic preconditioning-mediated cardioprotection is disrupted in heterozygous Flt-1 (VEGFR-1) knockout mice. JMol Cell Cardiol 2005;38:345-351.
55. Thirunavukkarasu M, Juhasz B, Zhan L, Menon VP, Tosaki A, Otani H et al. VEGFR1 (Flt-1 +/ -) gene knockout leads to the disruption of VEGF- mediated signaling through the nitric oxide/heme oxygenase pathway in ischemic preconditioned myocardium. Free Radic Biol Med 2007;42:1487-1495.
56. Kastrup J, Jorgensen E, Ruck A, Tagil K, Glogar D, Ruzyllo Wet al. Direct intramyocardial plasmid vascular endothelial growth factor-A165 gene therapy in patients with stable severe angina pectoris. A randomized double-blind placebo-controlled study: the Euroinject One trial. JAm Coll Cardiol 2005;45:982-988.
57. Fuchs S, Dib N, Cohen BM, Okubagzi P, Diethrich EB, Campbell A et al. A randomized, double-blind, placebo-controlled, multicenter, pilot study of the safety and feasibility of catheter-based intramyocardial injection of AdVEGF121 in patients with refractory advanced coronary artery disease. Catheter Cardiovasc Interv 2006;68:372-378.
58. Henry TD, Annex BH, McKendall GR, Azrin MA, Lopez JJ, Giordano FJ et al. The VIVA trial: Vascular endothelial growth factor in Ischemia for Vascular Angiogenesis. Circulation 2003;107:1359-1365.
59. Sodi-Pallares D, Testelli MR, Fishleder BL, Bisteni A, Medrano GA, Friedland C et al. Effects of an intravenous infusion of potassium-insulin- glucose solution on the electrocardiographic signs of myocardial infarction. A preliminary clinical report. Am J Cardiol1962;9:166-181.
60. Opie LH. Metabolism of free fatty acids, glucose and catecholamines in acute myocardial infarction. Relation to myocardial ischemia and infarct size. Am J Cardiol 1975;36:938-953.
61. Sack MN, Yellon DM. Insulin therapy as an adjunct to reperfusion after acute coronary ischemia: a proposed direct myocardial cell survival effect independent of metabolic modulation. J Am Coll Cardiol 2003;41:1404-1407.
62. DeBosch BJ, Muslin AJ. Insulin signaling pathways and cardiac growth. J Mol Cell Cardiol 2008;44:855-864.
63. Baines CP, Wang L, Cohen MV, Downey JM. Myocardial protection by insulin is dependent on phospatidylinositol 3-kinase but not protein kinase C or KATP channels in the isolated rabbit heart. Basic ResCardiol 1999;94:188-198.
64. Jonassen AK, Brar BK, Mjos OD, Sack MN, Latchman DS, Yellon DM. Insulin administered at reoxygenation exerts a cardioprotective effect in myocytes by a possible anti-apoptotic mechanism. J Mol Cell Cardiol 2000;32:757-764.
65. Jonassen AK, Sack MN, Mjos OD, Yellon DM. Myocardial protection by insulin at reperfusion requires early administration and is mediated via Akt and p70s6 kinase cell-survival signaling. Circ Res 2001;89:1191-1198.
66. Gao F, Gao E, Yue TL, Ohlstein EH, Lopez BL, Christopher TA et al. Nitric oxide mediates the antiapoptotic effect of insulin in myocardial ischemia-reperfusion: the roles of PI3-kinase, Akt, and endothelial nitric oxide synthase phosphorylation. Circulation 2002;105:1497-1502.
67. Fuglesteg BN, Suleman N, Tiron C, Kanhema T, Lacerda L, Andreasen TV et al. Signal transducer and activator of transcription 3 is involved in the cardioprotective signalling pathway activated by insulin therapy at reperfusion. Basic Res Cardiol 2008:444-453.
68. Boengler K, Hilfiker-Kleiner D, Drexler H, Heusch G, Schulz R. The myocardial JAK/STAT pathway: from protection to failure. Pharmacol Ther 2008;120:172-185.
69. Hausenloy DJ, Yellon DM. GLP-1 therapy: beyond glucose control. Circulation Heart Failure 2008;1:147-149.
70. Pierson RW Jr, Temin HM. The partial purification from calf serum of a fraction with multiplication-stimulating activity for chicken fibroblasts in cell culture and with non-suppressible insulin-like activity. J Cell Physiol 1972;79:319-330.
71. Suleiman MS, Singh RJ, Stewart CE. Apoptosis and the cardiac action of insulin-like growth factor I. Pharmacol Ther 2007;114:278-294.
72. Buerke M, Murohara T, Skurk C, Nuss C, Tomaselli K, Lefer AM. Cardio- protective effect of insulin-like growth factor I in myocardial ischemia followed by reperfusion. Proc Natl Acad Sci USA 1995;92:8031-8035.
73. Li Q, Li B, Wang X, Leri A, Jana KP, Liu Y et al. Overexpression of insulinlike growth factor-1 in mice protects from myocyte death after infarction, attenuating ventricular dilation, wall stress, and cardiac hypertrophy. J Clin Invest 1997;100:1991-1999.
74. Kulik G, Klippel A, Weber MJ. Antiapoptotic signalling by the insulin-like growth factor I receptor, phosphatidylinositol 3-kinase, and Akt. Mol Cell Biol 1997;17:1595-1606.
75. Parrizas M, Saltiel AR, LeRoith D. Insulin-like growth factor 1 inhibits apoptosis using the phosphatidylinositol 3'-kinase and mitogen- activated protein kinase pathways. J Biol Chem 1997;272:154-161.
76. Fujio Y, Nguyen T, Wencker D, Kitsis RN, Walsh K. Akt promotes survival of cardiomyocytes in vitro and protects against ischemia-reperfusion injury in mouse heart. Circulation 2000;101:660-667.
77. Yamashita K, Kajstura J, Discher DJ, Wasserlauf BJ, Bishopric NH, Anversa P et al. Reperfusion-activated Akt kinase prevents apoptosis in transgenic mouse hearts overexpressing insulin-like growth factor-1. Circ Res 2001;88:609-614.
78. Yamamura T, Otani H, Nakao Y, Hattori R, Osako M, Imamura H. IGF-I differentially regulates Bcl-xL and Bax and confers myocardial protection in the rat heart. Am J Physiol Heart Circ Physiol 2001; 280:H1191-H1200.
79. Pi Y, Goldenthal MJ, Marin-Garcia J. Mitochondrial involvement in IGF-1 induced protection of cardiomyocytes against hypoxia/reoxygenation injury. Mol Cell Biochem 2007;301:181-189.
80. Chao W, Matsui T, Novikov MS, Tao J, Li L, Liu H et al. Strategic advantages of insulin-like growth factor-I expression for cardioprotection.J Gene Med 2003;5:277-286.
81. Kaplan RC, Strickler HD, Rohan TE, Muzumdar R, Brown DL. Insulin-like growth factors and coronary heart disease. Cardiol Rev 2005;13:35-39.
82. Conti E, Andreotti F, Sciahbasi A, Riccardi P, Marra G, Menini E et al. Markedly reduced insulin-like growth factor-1 in the acute phase of myocardial infarction. J Am Coll Cardiol 2001;38:26-32.
83. Al Obaidi MK, Hon JK, Stubbs PJ, Barnes J, Amersey RA, Dahdal M et al. Plasma insulin-like growth factor-1 elevated in mild-to-moderate but not severe heart failure. Am Heart J 2001;142:E10.
84. Juul A, Scheike T, Davidsen M, Gyllenborg J, Jorgensen T. Low serum insulin-like growth factor I is associated with increased risk of ischemic heart disease: a population-based case-control study. Circulation 2002; 106:939-944.
85. Petretta M, Colao A, Sardu C, Scopacasa F, Marzullo P, Pivonello R et al. NT-proBNP, IGF-I and survival in patients with chronic heart failure. Growth Horm IGF Res 2007;17:288-296.
86. Donath MY, Jenni R, Brunner HP, Anrig M, Kohli S, Glatz Y et al. Cardiovascular and metabolic effects of insulin-like growth factor I at rest and during exercise in humans. J Clin Endocrinol Metab 1996;81:4089-4094.
87. Donath MY, Sutsch G, Yan XW, Piva B, Brunner HP, Glatz Y et al. Acute cardiovascular effects of insulin-like growth factor I in patients with chronic heart failure. J Clin Endocrinol Metab 1998;83:3177-3183.
88. Yoshida K, Taga T, Saito M, Suematsu S, Kumanogoh A, Tanaka T et al. Targeted disruption of gp130, a common signal transducer for the inter- leukin 6 family of cytokines, leads to myocardial and hematological disorders. Proc Natl Acad Sci USA 1996;93:407-411.
89. Pennica D, King KL, Shaw KJ, Luis E, Rullamas J, Luoh SM et al. Expression cloning of cardiotrophin 1, a cytokine that induces cardiac myocyte hypertrophy. Proc Natl Acad Sci USA 1995;92:1142-1146.
90. Sheng Z, Pennica D, Wood WI, Chien KR. Cardiotrophin-1 displays early expression in the murine heart tube and promotes cardiac myocyte survival. Development 1996;122:419-428.
91. Sheng Z, Knowlton K, Chen J, Hoshijima M, Brown JH, Chien KR. Cardio- trophin 1 (CT-1) inhibition of cardiac myocyte apoptosis via a mitogen- activated protein kinase-dependent pathway. Divergence from downstream CT-1 signals for myocardial cell hypertrophy. J Biol Chem 1997;272:5783-5791.
92. Stephanou A, Brar B, Heads R, Knight RD, Marber MS, Pennica D et al. Cardiotrophin-1 induces heat shock protein accumulation in cultured cardiac cells and protects them from stressful stimuli. J Mol Cell Cardiol 1998;30:849-855.
93. Brar BK, Stephanou A, Pennica D, Latchman DS. CT-1 mediated cardioprotection against ischaemic re-oxygenation injury is mediated by PI3 kinase, Akt and MEK1/2 pathways. Cytokine 2001;16:93-96.
94. Brar BK, Stephanou A, Liao Z, O'Leary RM, Pennica D, Yellon DM et al. Cardiotrophin-1 can protect cardiac myocytes from injury when added both prior to simulated ischaemia and at reoxygenation. Cardiovasc Res 2001;51:265- 274.
95. Liao Z, Brar BK, Cai Q, Stephanou A, O'Leary RM, Pennica D et al. Cardiotrophin-1 (CT-1) can protect the adult heart from injury when added both prior to ischaemia and at reperfusion. Cardiovasc Res 2002;53:902-910.
96. Ghosh S, Ng LL, Talwar S, Squire IB, Galinanes M. Cardiotrophin-1 protects the human myocardium from ischemic injury. Comparison with the first and second window of protection by ischemic preconditioning. Cardiovasc Res 2000;48:440-447.
97. Lopez N, Diez J, Fortuno MA. Characterization of the protective effects of cardiotrophin-1 against non-ischemic death stimuli in adult cardio- myocytes. Cytokine 2005;30:282-292.
98. Hishinuma S, Funamoto M, Fujio Y, Kunisada K, Yamauchi-Takihara K. Hypoxic stress induces cardiotrophin-1 expression in cardiac myocytes. Biochem Biophys Res Commun 1999;264:436-440.
99. Aoyama T, Takimoto Y, Pennica D, Inoue R, Shinoda E, Hattori R et al. Augmented expression of cardiotrophin-1 and its receptor component, gp130, in both left and right ventricles after myocardial infarction in the rat. J Mol Cell Cardiol 2000;32:1821-1830.
100. Gritman K, Van Winkle DM, Lorentz CU, Pennica D, Habecker BA. The lack of cardiotrophin-1 alters expression of interleukin-6 and leukemia inhibitory factor mRNA but does not impair cardiac injury response. Cytokine 2006;36:9-16.
101. Jougasaki M, Leskinen H, Larsen AM, Luchner A, Cataliotti A, Tachibana I et al. Ventricular cardiotrophin-1 activation precedes BNP in experimental heart failure. Peptides 2003;24:889-892.
102. Zolk O, Ng LL, O'Brien RJ, Weyand M, Eschenhagen T. Augmented expression of cardiotrophin-1 in failing human hearts is accompanied by diminished glycoprotein 130 receptor protein abundance. Circulation 2002;106:1442- 1446.
103. Pan J, Fukuda K, Saito M, Matsuzaki J, Kodama H, Sano Met al. Mechanical stretch activates the JAK/STAT pathway in rat cardiomyocytes. Circ Res 1999;84:1127-1136.
104. Asai S, Saito Y, Kuwahara K, Mizuno Y, Yoshimura M, Higashikubo C et al. The heart is a source of circulating cardiotrophin-1 in humans. Biochem Biophys Res Commun 2000;279:320-323.
105. Talwar S, Squire IB, Downie PF, Davies JE, Ng LL. Plasma N terminal pro- brain natriuretic peptide and cardiotrophin 1 are raised in unstable angina. Heart 2000;84:421-424.
106. Talwar S, Squire IB, O'Brien RJ, Downie PF, Davies JE, Ng LL. Plasma cardiotrophin-1 following acute myocardial infarction: relationship with left ventricular systolic dysfunction. Clin Sci (Lond) 2002; 102:9-14.
107. Talwar S, Downie PF, Squire IB, Davies JE, Barnett DB, Ng LL. Plasma N- terminal pro BNP and cardiotrophin-1 are elevated in aortic stenosis. Eur J Heart Fail 2001;3:15-19.
108. Talwar S, Squire IB, Davies JE, Ng LL. The effect of valvular regurgitation on plasma Cardiotrophin-1 in patients with normal left ventricular systolic function. Eur J Heart Fail 2000;2:387-391.
109. Gonzalez A, Lopez B, Martin-Raymondi D, Lozano E, Varo N, Barba J et al. Usefulness of plasma cardiotrophin-1 in assessment of left ventricular hypertrophy regression in hypertensive patients. J Hypertens 2005;23:2297-2304.
110. Talwar S, Downie PF, Squire IB, Barnett DB, Davies JD, Ng LL. An immu- noluminometric assay for cardiotrophin-1: a newly identified cytokine is present in normal human plasma and is increased in heart failure. Biochem Biophys Res Commun 1999;261:567-571.
111. Talwar S, Squire IB, Downie PF, O'Brien RJ, Davies JE, Ng LL. Elevated circulating cardiotrophin-1 in heart failure: relationship with parameters of left ventricular systolic dysfunction. Clin Sci (Lond) 2000;99:83-88.
112. Pennica D, Shaw KJ, Swanson TA, Moore MW, Shelton DL, Zioncheck KA et al. Cardiotrophin-1. Biological activities and binding to the leukemia inhibitory factor receptor/gp130 signaling complex. J Biol Chem 1995; 270:10915- 10922.
113. Carpenter CL, Auger KR, Chanudhuri M, Yoakim M, Schaffhausen B, Shoelson S et al. Phosphoinositide 3-kinase is activated by phosphopep- tides that bind to the SH2 domains of the 85-kDa subunit. J Biol Chem 1993;268:9478-9483.
114. Gu H, Maeda H, Moon JJ, Lord JD, Yoakim M, Nelson BH et al. New role for Shc in activation of the phosphatidylinositol 3-kinase/Akt pathway. Mol Cell Biol 2000;20:7109-7120.
115. Kuwahara K, Saito Y, Kishimoto I, Miyamoto Y, Harada M, Ogawa E et al. Cardiotrophin-1 phosphorylates akt and BAD, and prolongs cell survival via a PI3K-dependent pathway in cardiac myocytes. J Mol Cell Cardiol 2000;32:1385-1394.
116. Craig R, Wagner M, McCardle T, Craig AG, Glembotski CC. The cytopro- tective effects of the glycoprotein 130 receptor-coupled cytokine, cardiotrophin-1, require activation of NF-kappa B. J Biol Chem 2001;276:37621-37629.
117. Ruixing Y, Dezhai Y, Jiaquan L. Effects of cardiotrophin-1 on hemody- namics and cardiomyocyte apoptosis in rats with acute myocardial infarction. J Med Invest 2004;51:29-37.
118. Vaughan J, Donaldson C, Bittencourt J, Perrin MH, Lewis K, Sutton S et al. Urocortin, a mammalian neuropeptide related to fish urotensin I and to corticotropin-releasing factor. Nature 1995;378:287-292.
119. Takahashi K, Totsune K, Murakami O, Shibahara S. Urocortins as cardiovascular peptides. Peptides 2004;25:1723-1731.
120. Davidson SM, Rybka AE, Townsend PA. The powerful cardioprotective effects of urocortin and the corticotropin releasing hormone (CRH) family. Biochem Pharmacol 2009;77:141-150.
121. Parkes DG, Vaughan J, Rivier J, Vale W, May CN. Cardiac inotropic actions of urocortin in conscious sheep. Am J Physiol 1997; 272: H2115-H2122.
122. Coste SC, Kesterson RA, Heldwein KA, Stevens SL, Heard AD, Hollis JH et al. Abnormal adaptations to stress and impaired cardiovascular function in mice lacking corticotropin-releasing hormone receptor-2. NatGenet 2000;24:403-409.
123. Okosi A, Brar BK, Chan M, D'souza L, Smith E, Stephanou A et al. Expression and protective effects of urocortin in cardiac myocytes.Neuropeptides 1998;32:167-171.
124. Knight RA, Chen-Scarabelli C, Yuan Z, McCauley RB, Di Rezze J, Scarabelli GM et al. Cardiac release of urocortin precedes the occurrence of irreversible myocardial damage in the rat heart exposed to ischemia/reperfusion injury. FEBS Lett 2008;582:984-990.
125. Brar BK, Stephanou A, Okosi A, Lawrence KM, Knight RA, Marber MS et al. CRH-like peptides protect cardiac myocytes from lethal ischaemic injury. Mol Cell Endocrinol 1999;158:55-63.
126. Brar BK, Jonassen AK, Stephanou A, Santilli G, Railson J, Knight RA et al. Urocortin protects against ischemic and reperfusion injury via a MAPK- dependent pathway. J Biol Chem 2000;275:8508-8514.
127. Brar BK, Stephanou A, Knight R, Latchman DS. Activation of protein kinase B/Akt by urocortin is essential for its ability to protect cardiac cells against hypoxia/reoxygenation-induced cell death. J Mol Cell Cardiol 2002;34:483-492.
128. Stenzel P, Kesterson R, Yeung W, Cone RD, Rittenberg MB, Stenzel-Poore MP. Identification of a novel murine receptor for corticotropin-releasing hormone expressed in the heart. Mol Endocrinol 1995;9:637-645.
129. Chen R, Lewis KA, Perrin MH, Vale WW. Expression cloning of a human corticotropin-releasing-factor receptor. Proc Natl Acad Sci USA 1993;90:8967-8971.
130. Kimura Y, Takahashi K, Totsune K, Muramatsu Y, Kaneko C, Darnel AD et al. Expression of urocortin and corticotropin-releasing factor receptor subtypes in the human heart. J Clin Endocrinol Metab 2002;87:340-346.
131. Bondeva T, Pirola L, Bulgarelli-Leva G, Rubio I, Wetzker R, Wymann MP. Bifurcation of lipid and protein kinase signals of PI3Kgamma to the protein kinases PKB and MAPK. Science 1998;282:293-296.
132. Schulman D, Latchman DS, Yellon DM. Urocortin protects the heart from reperfusion injury via upregulation of p42/p44 MAPK signaling pathway. Am J Physiol Heart Circ Physiol 2002;283:H1481-H1488.
133. Lawrence KM, Chanalaris A, Scarabelli T, Hubank M, Pasini E, Townsend PA et al. K(ATP) channel gene expression is induced byurocor- tin and mediates its cardioprotective effect. Circulation 2002;106:1556-1562.
134. Gordon JM, Dusting GJ, Woodman OL, Ritchie RH. Cardioprotective action of CRF peptide urocortin against simulated ischemia in adult rat cardiomyocytes. Am J Physiol Heart Circ Physiol 2003;284:H330-H336.
135. Lawrence KM, Townsend PA, Davidson SM, Carroll CJ, Eaton S, Hubank M et al. The cardioprotective effect of urocortin during ischaemia/reper- fusion involves the prevention of mitochondrial damage. Biochem Biophys Res Commun 2004;321:479-486.
136. Lawrence KM, Scarabelli TM, Turtle L, Chanalaris A, Townsend PA, Carroll CJ et al. Urocortin protects cardiac myocytes from ischemia/ reperfusion injury by attenuating calcium-insensitive phospholipase A2 gene expression. FASEB J 2003;17:2313-2315.
137. Townsend PA, Davidson SM, Clarke SJ, Khaliulin I, Carroll CJ, Scarabelli TM et al. Urocortin prevents mitochondrial permeability transition in response to reperfusion injury indirectly by reducing oxidative stress. Am J Physiol Heart Circ Physiol 2007;293:H928-H938.
138. Valentim L, Laurence KM, Townsend PA, Carroll CJ, Soond S, Scarabelli TM et al. Urocortin inhibits Beclin1-mediated autophagic cell death in cardiac myocytes exposed to ischaemia/reperfusion injury. J Mol Cell Cardiol 2006;40:846-852.
139. Brar BK, Jonassen AK, Egorina EM, Chen A, Negro A, Perrin MH et al. Urocortin-II and urocortin-III are cardioprotective against ischemia reperfusion injury: an essential endogenous cardioprotective role for corticotropin releasing factor receptor type 2 in the murine heart. Endocrinology 2004;145:24-35.
140. Chanalaris A, Lawrence KM, Stephanou A, Knight RD, Hsu SY, Hsueh AJ et al. Protective effects of the urocortin homologues stresscopin (SCP) and stresscopin-related peptide (SRP) against hypoxia/reoxygenation injury in rat neonatal cardiomyocytes. J Mol Cell Cardiol 2003;35:1295-1305.
141. Nishikimi T, Miyata A, Horio T, Yoshihara F, Nagaya N, Takishita S et al. Urocortin, a member of the corticotropin-releasing factor family, in normal and diseased heart. Am J Physiol Heart Circ Physiol 2000;279:H3031-H3039.
142. Ikeda K, Tojo K, Tokudome G, Ohta M, Sugimoto K, Tamura T et al. Cardiac expression of urocortin (Ucn) in diseased heart; preliminary results on possible involvement of Ucn in pathophysiology of cardiac diseases. Mol Cell Biochem 2003;252:25-32.
143. Ng LL, Loke IW, O'Brien RJ, Squire IB, Davies JE. Plasma urocortin in human systolic heart failure. Clin Sci (Lond) 2004;106:383-388.
144. Davis ME, Pemberton CJ, Yandle TG, Lainchbury JG, Rademaker MT, Nicholls MG et al. Urocortin-1 infusion in normal humans. J Clin Endocrinol Metab 2004;89:1402-1409.
145. Davis ME, Pemberton CJ, Yandle TG, Lainchbury JG, Rademaker MT, Nicholls MG et al. Effect of urocortin 1 infusion in humans with stable congestive cardiac failure. Clin Sci (Lond) 2005;109:381-388.
146. Davis ME, Pemberton CJ, Yandle TG, Fisher SF, Lainchbury JG, Frampton CM et al. Urocortin 2 infusion in healthy humans: hemody- namic, neurohormonal, and renal responses. J Am Coll Cardiol 2007; 49:461-471.
147. Davis ME, Pemberton CJ, Yandle TG, Fisher SF, Lainchbury JG, Frampton CM et al. Urocortin 2 infusion in human heart failure. Eur Heart J 2007;28:2589-2597.
148. Hermonat PL, Li D, Yang B, Mehta JL. Mechanism of action and delivery possibilities for TGFbeta1 in the treatment of myocardial ischemia. Car-diovasc Res 2007;74:235-243.
149. Ruiz-Ortega M, Rodriguez-Vita J, Sanchez-Lopez E, Carvajal G, Egido J. TGF-beta signaling in vascular fibrosis. Cardiovasc Res 2007; 74:196-206.
150. Lefer AM, Tsao P, Aoki N, Palladino MA Jr. Mediation of cardioprotection by transforming growth factor-beta. Science 1990;249:61-64.
151. Lefer AM, Ma XL, Weyrich AS, Scalia R. Mechanism of the cardioprotec- tive effect of transforming growth factor beta 1 in feline myocardial ischemia and reperfusion. Proc Natl Acad Sci USA 1993;90:1018-1022.
152. Keller M, Kong Y, Robertson AD, Horwitz L. Prevention of coronary vascular abnormalities early in reperfusion with TGF-beta may not prevent late coronary vascular injury. J Cardiovasc Pharmacol 1997;30:197-204.
153. Yang BC, Zander DS, Mehta JL. Hypoxia-reoxygenation-induced apopto- sis in cultured adult rat myocytes and the protective effect of platelets and transforming growth factor-beta(1). J Pharmacol Exp Ther 1999; 291:733-738.
154. Baxter GF, Mocanu MM, Brar BK, Latchman DS, Yellon DM. Cardioprotec- tive effects of transforming growth factor-beta1 during early reoxy- genation or reperfusion are mediated by p42/p44 MAPK. J Cardiovasc Pharmacol 2001;38:930-939.
155. Chen H, Li D, Saldeen T, Mehta JL. TGF-beta(1) modulates NOS expression and phosphorylation of Akt/PKB in rat myocytes exposed to hypoxia-reoxygenation. Am J Physiol Heart Circ Physiol 2001;281:H1035-H1039.
156. Mehta JL, Chen HJ, Li DY. Protection of myocytes from hypoxia-reoxygenation injury by nitric oxide is mediated by modulation of transforming growth factor-beta1. Circulation 2002;105:2206-2211.
157. Gnecchi M, Zhang Z, Ni A, Dzau VJ. Paracrine mechanisms in adult stem cell signaling and therapy. Circ Res 2008;103:1204-1219.
158. Rosenblatt-Velin N, Lepore MG, Cartoni C, Beermann F, Pedrazzini T. FGF-2 controls the differentiation of resident cardiac precursors into functional cardiomyocytes. J Clin Invest 2005;115:1724-1733.
159. Kofidis T, de Bruin JL, Yamane T, Balsam LB, Lebl DR, Swijnenburg RJ et al. Insulin-like growth factor promotes engraftment, differentiation, and functional improvement after transfer of embryonic stem cells for myocardial restoration. Stem Cells 2004;22:1239-1245.
160. Ghosh-Choudhury N, Abboud SL, Mahimainathan L, Chandrasekar B, Choudhury GG. Phosphatidylinositol 3-kinase regulates bone morpho- genetic protein-2 (BMP-2)-induced myocyte enhancer factor 2A-dependent transcription of BMP-2 gene in cardiomyocyte precursor cells. J Biol Chem 2003;278:21998-22005.
161. Schultheiss TM, Burch JB, Lassar AB. A role for bone morphogenetic proteins in the induction of cardiac myogenesis. Genes Dev 1997;11:451- 462.
162. Hahn JY, Cho HJ, Kang HJ, Kim TS, Kim MH, Chung JH et al. Pre-treatment of mesenchymal stem cells with a combination of growth factors enhances gap junction formation, cytoprotective effect on car- diomyocytes, and therapeutic efficacy for myocardial infarction. JAm Coll Cardiol 2008;51:933-943.
163. Cuevas P, Carceller F, Cuevas B, Gimenez-Gallego G, Martinez-Coso V. A non-mitogenic form of acidic fibroblast growth factor reduces neutrophil infiltration in rat ischemic reperfused heart. Eur J Med Res 1997; 2:139-143.
164. Cuevas P, Reimers D, Carceller F, Martinez-Coso V, Redondo-Horcajo M, Saenz de Tejada I et al. Fibroblast growth factor-1 prevents myocardial apoptosis triggered by ischemia reperfusion injury. Eur J Med Res 1997;2:465-468.
165. Horrigan MC, Malycky JL, Ellis SG, Topol EJ, Nicolini FA. Reduction in myocardial infarct size by basic fibroblast growth factor following coronary occlusion in a canine model. Int J Cardiol 1999;68(Suppl. 1):S85-S91.
166. Buehler A, Martire A, Strohm C, Wolfram S, Fernandez B, Palmen M et al. Angiogenesis-independent cardioprotection in FGF-1 transgenic mice. Cardiovasc Res 2002;55:768-777.
167. Palmen M, Daemen MJ, De Windt LJ, Willems J, Dassen WR, Heeneman S et al. Fibroblast growth factor-1 improves cardiac functional recovery and enhances cell survival after ischemia and reperfusion: a fibroblast growth factor receptor, protein kinase C, and tyrosine kinase-dependent mechanism. J Am Coll Cardiol 2004;44:1113-1123.
168. House SL, Branch K, Newman G, Doetschman T, Schultz JJ. Cardioprotection induced by cardiac-specific overexpression of fibroblast growth factor-2 is mediated by the MAPK cascade. Am J Physiol Heart Circ Physiol 2005;289:H2167-H2175.
169. Gao F, Tao L, Yan W, Gao E, Liu HR, Lopez BL et al. Early anti-apoptosis treatment reduces myocardial infarct size after a prolonged reperfusion. Apoptosis 2004;9:553-559.
170. Fuglesteg BN, Tiron C, Jonassen AK, Mjos OD, Ytrehus K. Pre-treatment with insulin before ischemia reduces infarct size in Langendorff perfused rat hearts. Acta Physiol (Oxf) 2009;195:273-282.
171. Vogt AM, Htun P, Kluge A, Zimmermann R, Schaper W. Insulin-like growth factor-II delays myocardial infarction in experimental coronary artery occlusion. Cardiovasc Res 1997;33:469-477.
172. Wang L, Ma W, Markovich R, Chen JW, Wang PH. Regulation of cardio- myocyte apoptotic signaling by insulin-like growth factor I. Circ Res 1998;83:516-522.
173. Otani H, Yamamura T, Nakao Y, Hattori R, Kawaguchi H, Osako M et al. Insulin-like growth factor-I improves recovery of cardiac performance during reperfusion in isolated rat heart by a wortmannin-sensitive mechanism. J Cardiovasc Pharmacol 2000;35:275-281.
174. Hong F, Kwon SJ, Jhun BS, Kim SS, Ha J, Kim SJ et al. Insulin-like growth factor-1 protects H9c2 cardiac myoblasts from oxidative stress-induced apoptosis via phosphatidylinositol 3-kinase and extracellular signal- regulated kinase pathways. Life Sci 2001;68:1095-1105.
175. Scarabelli TM, Pasini E, Stephanou A, Comini L, Curello S, Raddino R et al. Urocortin promotes hemodynamic and bioenergetic recovery and improves cell survival in the isolated rat heart exposed to ische- mia/reperfusion. J Am Coll Cardiol 2002;40:155-161.
176. Cserepes B, Jancso G, Gasz B, Racz B, Ferenc A, Benko L et al. Cardio- protective action of urocortin in early pre- and postconditioning. Ann NY Acad Sci 2007;1095:228-239.
177. Mehta JL, Yang BC, Strates BS, Mehta P. Role of TGF-beta1 in platelet- mediated cardioprotection during ischemia-reperfusion in isolated rat hearts. Growth Factors 1999;16:179-190.
178. Chen H, Li D, Saldeen T, Mehta JL. TGF-beta 1 attenuates myocardial ischemia-reperfusion injury via inhibition of upregulation of MMP-1. Am J Physiol Heart Circ Physiol 2003;284:H1612-H1617.